Feeding Strategies Around Blood Transfusions for Necrotizing Enterocolitis
(WHEAT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the best feeding approach for very premature babies (born before 30 weeks) during blood transfusions to reduce the risk of Necrotizing Enterocolitis (NEC), a severe intestinal disease. Researchers compare two methods: continuing feeds during transfusion (Continued feeds around transfusion) or pausing feeds for a short period around the transfusion (Withholding feeds around transfusion). The trial is open to preterm infants in Canada and the UK who have not yet had a blood transfusion with feeds and have no major gut issues. As an unphased trial, this study offers a unique opportunity to contribute to important research that could improve care for very premature infants.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It focuses on feeding strategies around blood transfusions for very premature infants.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has examined the effects of both continuing and stopping feeds during blood transfusions in premature babies to assess safety. When feeds continue, researchers have investigated whether feeding during a blood transfusion increases the risk of necrotizing enterocolitis (NEC), a serious bowel condition. Some studies suggest a possible link between feeding during transfusions and NEC, but more data is needed.
Conversely, stopping feeds during transfusions might reduce the risk of NEC by lessening stress on the baby's gut. However, this idea stems from observations and lacks thorough testing in controlled studies. Concerns also exist that stopping feeds could negatively affect the baby's nutrition and growth.
Both approaches are common in neonatal care and are generally considered safe, but further research is needed to determine which is more effective in preventing NEC.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores different feeding strategies around blood transfusions for infants with necrotizing enterocolitis (NEC), a serious intestinal condition. Typically, feeding is paused during transfusions to prevent complications. However, this trial is investigating whether continuing feeds could be beneficial, potentially offering a more stable nutritional intake. By comparing continued feeding with the traditional method of withholding feeds, the trial aims to determine the safest and most effective approach, potentially leading to improved care for vulnerable infants.
What evidence suggests that this trial's treatments could be effective for reducing Necrotizing Enterocolitis?
This trial will compare two feeding strategies around the time of a blood transfusion for very premature infants to prevent necrotizing enterocolitis (NEC), a serious gut condition. One arm of the trial continues feeds during the transfusion, while the other withholds feeds. Research has shown no clear consensus on which approach is more effective. Some studies suggest that continuing feeds during a transfusion does not affect oxygen delivery to the baby's gut. However, observations indicate that stopping feeds might reduce NEC risk by lessening gut stress, though controlled studies have not proven this potential benefit. Both methods are currently used in hospitals, highlighting the ongoing debate about the best approach.12346
Who Is on the Research Team?
Balpreet Singh, MD
Principal Investigator
IWK Health, Canada
Jon Dorling, MD
Principal Investigator
Princess Anne Hospital, UK
Chris Gale, MD
Principal Investigator
Imperial College London, UK
Are You a Good Fit for This Trial?
This trial is for very premature infants born before 30 weeks of gestation. It's not suitable for babies with major GIT abnormalities, those whose parents opt out, or who have had a blood transfusion with feeds or a previous episode of NEC/SIP before their first transfusion.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants are randomized to either withhold or continue enteral feeds around blood transfusion until 34(+6) weeks gestational age
Follow-up
Participants are monitored for safety and effectiveness after treatment, including NEC, ROP, severe brain injury, and other outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Continued feeds around transfusion
- Withholding feeds around transfusion
Find a Clinic Near You
Who Is Running the Clinical Trial?
IWK Health Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Imperial College London
Collaborator